Akebia Therapeutics, Inc. – NASDAQ:AKBA
Akebia Therapeutics stock price today
$3.06
+1.11
+56.92%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
Akebia Therapeutics stock price monthly change
+54.76%
month
Akebia Therapeutics stock price quarterly change
+54.76%
quarter
Akebia Therapeutics stock price yearly change
+62.50%
year
Akebia Therapeutics key metrics
Market Cap | 394.90M |
Enterprise value | 123.79M |
P/E | -1.35 |
EV/Sales | 0.42 |
EV/EBITDA | -3.15 |
Price/Sales | 0.40 |
Price/Book | 12.76 |
PEG ratio | -0.01 |
EPS | -0.22 |
Revenue | 187.22M |
EBITDA | -6.88M |
Income | -43.03M |
Revenue Q/Q | -18.74% |
Revenue Y/Y | -30.92% |
Profit margin | -31.63% |
Oper. margin | -24.13% |
Gross margin | 68.9% |
EBIT margin | -24.13% |
EBITDA margin | -3.68% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAkebia Therapeutics stock price history
Akebia Therapeutics stock forecast
Akebia Therapeutics financial statements
| Jun 2023 | 56.37M | -11.17M | -19.82% |
|---|---|---|---|
| Sep 2023 | 42.04M | -14.48M | -34.46% |
| Dec 2023 | 56.19M | 614K | 1.09% |
| Mar 2024 | 32.60M | -17.98M | -55.16% |
| Mar 2024 | 32.60M | -17.98M | -55.16% |
|---|---|---|---|
| Sep 2025 | 47.33M | -7.41M | -15.67% |
| Oct 2025 | 47.28M | -8.19M | -17.34% |
| Dec 2025 | 51.78M | -7.17M | -13.85% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 253712000 | 280.51M | 110.57% |
|---|---|---|---|
| Sep 2023 | 234998000 | 274.42M | 116.78% |
| Dec 2023 | 241703000 | 272.28M | 112.65% |
| Mar 2024 | 225477000 | 252.73M | 112.09% |
| Jun 2023 | 3.62M | 0 | -8M |
|---|---|---|---|
| Sep 2023 | -7.16M | 0 | 50K |
| Dec 2023 | -2.30M | 0 | -1.29M |
| Mar 2024 | -19.43M | 0 | 18.47M |
Akebia Therapeutics alternative data
| Aug 2023 | 204 |
|---|---|
| Sep 2023 | 204 |
| Oct 2023 | 204 |
| Nov 2023 | 204 |
| Dec 2023 | 204 |
| Jan 2024 | 204 |
| Feb 2024 | 204 |
| Mar 2024 | 167 |
| Apr 2024 | 167 |
| May 2024 | 167 |
| Jun 2024 | 167 |
| Jul 2024 | 167 |
Akebia Therapeutics other data
25.28%
-6.84%
of AKBA is owned by hedge funds
65
-18
48.12M
-9.55M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 203429 |
| May 2024 | 0 | 46856 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HADAS NICOLE R. officer: SVP, Chief Legal Officer | Common Stock | 12,016 | $1.26 | $15,140 | ||
Sale | DAHAN MICHEL officer: SVP, Chi.. | Common Stock | 34,840 | $1.26 | $43,898 | ||
Sale | DAHAN MICHEL officer: SVP, Chi.. | Common Stock | 8,661 | $1.58 | $13,684 | ||
Sale | HADAS NICOLE R. officer: SVP, Chief Legal Officer | Common Stock | 5,974 | $1.58 | $9,439 | ||
Sale | BUTLER JOHN P. director, officer: CEO and Pres.. | Common Stock | 46,570 | $1.58 | $73,581 | ||
Sale | BURKE STEVEN KEITH officer: SVP, Chi.. | Common Stock | 7,169 | $1.58 | $11,327 | ||
Sale | HADAS NICOLE R. officer: SVP, Chief Legal Officer | Common Stock | 7,411 | $1.52 | $11,265 | ||
Sale | DAHAN MICHEL officer: SVP, Chi.. | Common Stock | 10,744 | $1.52 | $16,331 | ||
Sale | BURKE STEVEN KEITH officer: SVP, Chi.. | Common Stock | 8,367 | $1.52 | $12,718 | ||
Sale | BUTLER JOHN P. director, officer: CEO and Pres.. | Common Stock | 37,733 | $1.52 | $57,354 |
| Patent |
|---|
Grant Filling date: 31 Mar 2016 Issue date: 10 May 2022 |
Grant Utility: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Filling date: 6 Jul 2020 Issue date: 8 Mar 2022 |
Application SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOF Filling date: 15 Jun 2021 Issue date: 10 Feb 2022 |
Application Filling date: 2 Oct 2019 Issue date: 2 Dec 2021 |
Grant Utility: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Filling date: 10 Feb 2020 Issue date: 20 Jul 2021 |
Application Filling date: 12 Nov 2020 Issue date: 8 Jul 2021 |
Application Filling date: 22 Jun 2020 Issue date: 13 May 2021 |
Application Filling date: 6 Jul 2020 Issue date: 29 Apr 2021 |
Application Filling date: 8 May 2019 Issue date: 11 Mar 2021 |
Application SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOF Filling date: 10 Feb 2020 Issue date: 5 Nov 2020 |
| Quarter | Transcript |
|---|---|
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 25 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 8 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 9 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. John P. Butler MBA (1964) Chief Executive Officer, Pres & Director | $1,200,000 |
| Dr. Steven Keith Burke (1961) Senior Vice President of R&D and Chief Medical Officer | $681,870 |
| Mr. Dell Faulkingham (1973) Senior Vice President & Chief Commercial Officer | $660,040 |
| Mr. Michel Dahan (1979) Senior Vice President & Chief Operating Officer | $655,140 |
| Mr. David A. Spellman (1977) Senior Vice President, Chief Financial Officer & Treasurer | $591,060 |
| Mr. Jason A. Amello (1968) Executive Officer | $435,660 |
-
What's the price of Akebia Therapeutics stock today?
One share of Akebia Therapeutics stock can currently be purchased for approximately $3.06.
-
When is Akebia Therapeutics's next earnings date?
Unfortunately, Akebia Therapeutics's (AKBA) next earnings date is currently unknown.
-
Does Akebia Therapeutics pay dividends?
No, Akebia Therapeutics does not pay dividends.
-
How much money does Akebia Therapeutics make?
Akebia Therapeutics has a market capitalization of 394.90M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 33.49% to 194.62M US dollars.
-
What is Akebia Therapeutics's stock symbol?
Akebia Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AKBA".
-
What is Akebia Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Akebia Therapeutics?
Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Akebia Therapeutics's key executives?
Akebia Therapeutics's management team includes the following people:
- Mr. John P. Butler MBA Chief Executive Officer, Pres & Director(age: 61, pay: $1,200,000)
- Dr. Steven Keith Burke Senior Vice President of R&D and Chief Medical Officer(age: 64, pay: $681,870)
- Mr. Dell Faulkingham Senior Vice President & Chief Commercial Officer(age: 52, pay: $660,040)
- Mr. Michel Dahan Senior Vice President & Chief Operating Officer(age: 46, pay: $655,140)
- Mr. David A. Spellman Senior Vice President, Chief Financial Officer & Treasurer(age: 48, pay: $591,060)
- Mr. Jason A. Amello Executive Officer(age: 57, pay: $435,660)
-
How many employees does Akebia Therapeutics have?
As Jul 2024, Akebia Therapeutics employs 167 workers.
-
When Akebia Therapeutics went public?
Akebia Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 20 Mar 2014.
-
What is Akebia Therapeutics's official website?
The official website for Akebia Therapeutics is akebia.com.
-
Where are Akebia Therapeutics's headquarters?
Akebia Therapeutics is headquartered at 245 First Street, Cambridge, MA.
-
How can i contact Akebia Therapeutics?
Akebia Therapeutics's mailing address is 245 First Street, Cambridge, MA and company can be reached via phone at +61 78712098.
Akebia Therapeutics company profile:
Akebia Therapeutics, Inc.
akebia.comExchange:
NASDAQ
Full time employees:
167
Industry:
Biotechnology
Sector:
Healthcare
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
245 First Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001517022
ISIN: US00972D1054
CUSIP: 00972D105
